FDA批准古塞库单抗用于儿童银屑病和关节炎，而麻疹疫苗接种率降至群体免疫阈值以下-动脉网

FDA Approves Guselkumab for Pediatric Psoriasis and Arthritis as Measles Vaccination Rates Fall Below Herd Immunity Threshold

GeneOnline 等信源发布 2025-09-30 19:06



可切换为仅中文







by Mark Chiang

马克·蒋

Share To

分享到

Recent developments in the pharmaceutical and healthcare sectors highlight ongoing challenges and advancements. New data reveals that global measles vaccination rates remain below the levels required to achieve herd immunity, raising concerns about potential outbreaks. Meanwhile, the U.S. Food and Drug Administration (FDA) has approved guselkumab for treating pediatric patients with plaque psoriasis and psoriatic arthritis, marking a significant step in expanding treatment options for children.

制药和医疗保健领域近期的发展突显了持续的挑战与进步。最新数据显示，全球麻疹疫苗接种率仍低于实现群体免疫所需的水平，这引发了对潜在疫情爆发的担忧。与此同时，美国食品药品监督管理局（FDA）已批准古塞库单抗用于治疗患有斑块型银屑病和银屑病关节炎的儿童患者，这标志着在扩大儿童治疗选择方面迈出了重要一步。

Additionally, AbbVie has announced the commencement of construction on a new active pharmaceutical ingredient (API) manufacturing facility in Illinois..

此外，艾伯维宣布开始在伊利诺伊州建设一个新的活性药物成分（API）制造工厂。

The latest findings on measles vaccination coverage indicate that immunization rates have not reached the 95% threshold necessary to prevent widespread transmission of the disease. This gap leaves many communities vulnerable to outbreaks, particularly in regions where vaccine access or uptake remains limited.

最新关于麻疹疫苗接种覆盖率的研究结果表明，免疫接种率尚未达到防止疾病广泛传播所需的95%门槛。这一缺口使许多社区容易受到疫情爆发的影响，尤其是在疫苗获取或接种率仍然有限的地区。

In other news, guselkumab, an interleukin-23 inhibitor previously approved for adults, has now received FDA approval for use in children aged six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This approval provides a new therapeutic option for managing these chronic conditions in younger populations.

此外，古塞库单抗（guselkumab）是一种先前已获批用于成人的白介素-23抑制剂，现在已获得FDA批准，可用于六岁及以上患有中度至重度斑块型银屑病或活动性银屑病关节炎的儿童。这一批准为管理这些年轻人群中的慢性疾病提供了新的治疗选择。

Separately, AbbVie has begun construction on a new API manufacturing site in North Chicago, Illinois. The facility is expected to enhance domestic production capabilities and support the company’s growing portfolio of treatments..

此外，艾伯维已开始在伊利诺伊州北芝加哥建设一个新的原料药生产厂。该工厂预计将增强国内生产能力，并支持公司不断增长的治疗产品组合。

These updates underscore both persistent public health challenges and progress within the pharmaceutical industry as it addresses unmet medical needs and expands infrastructure capacity.

这些更新既突显了持续的公共卫生挑战，也体现了制药行业在应对未满足的医疗需求和扩大基础设施能力方面取得的进展。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建议和反馈，请联系我们。

Date: September 30, 2025

日期：2025年9月30日

Study Finds Timing of Prenatal Stress Influences Infant Stress Responses by Gender

研究发现，产前压力的时间对婴儿的压力反应有性别差异影响

Webinar Explores AI Applications in Medical Affairs With Focus on Data Analysis and Decision-Making